PM
TVRD

Prosight Management’s Tvardi Therapeutics TVRD Stock Holding History

Prosight Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,778
Closed -$2.17M – 51
2021
Q1 		$2.17M Sell
2,778
-5,390
-66% -$3.69M 1.78% 21
2020
Q4 		$4.45M Buy
8,168
+3,317
+68% +$1.74M 2.06% 18
2020
Q3 		$2.22M Buy
4,851
+2,435
+101% +$1.41M 1.06% 29
2020
Q2 		$1.49M Buy
+2,416
New +$1.33M 0.64% 37

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Prosight Management's TVRD Position: Q2 2021 in Review

Prosight Management sold out of Tvardi Therapeutics (TVRD) in Q2 2021, closing a stake of 2,778 shares — an estimated $2.17M sold.

Prosight Management first reported a position in TVRD in Q2 2020 and held it in 4 quarters. The position peaked at $4.45M in Q4 2020. 173 funds tracked by Wall St. Rank hold TVRD as of Q2 2021.

  • Prosight Management reported no remaining Tvardi Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Prosight Management sold 2,778 Tvardi Therapeutics shares in Q2 2021, an estimated $2.17M.
  • Prosight Management first reported a position in Tvardi Therapeutics in Q2 2020 and held it in 4 quarters.
  • Prosight Management's Tvardi Therapeutics position peaked at $4.45M in Q4 2020.
  • 173 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2021.

Based on Prosight Management's 13F filing for Q2 2021, filed 13 Aug 2021.